19,209 Shares in Sanofi (NASDAQ:SNY) Purchased by JPL Wealth Management LLC

JPL Wealth Management LLC purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 19,209 shares of the company's stock, valued at approximately $955,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Rise Advisors LLC boosted its holdings in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company's stock worth $25,000 after buying an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the fourth quarter worth about $27,000. Venturi Wealth Management LLC raised its position in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company's stock worth $27,000 after purchasing an additional 332 shares during the period. McIlrath & Eck LLC raised its position in shares of Sanofi by 143.3% during the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company's stock worth $30,000 after purchasing an additional 361 shares during the period. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its position in shares of Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company's stock worth $37,000 after purchasing an additional 400 shares during the period. Institutional investors own 10.04% of the company's stock.

Sanofi Stock Up 2.9 %

Shares of Sanofi stock traded up $1.41 on Wednesday, reaching $50.36. 2,119,354 shares of the company were exchanged, compared to its average volume of 1,985,697. Sanofi has a one year low of $42.63 and a one year high of $55.72. The company has a market capitalization of $127.39 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 1.35 and a beta of 0.61. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $48.25 and a 200 day moving average of $48.20.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.96. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The company had revenue of $11.36 billion for the quarter, compared to analysts' expectations of $11.75 billion. On average, equities research analysts forecast that Sanofi will post 4.12 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi's payout ratio is presently 74.37%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SNY. TheStreet lowered Sanofi from a "b" rating to a "c" rating in a research report on Friday, February 9th. Morgan Stanley began coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 target price on the stock. Finally, StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.